New Analyst Ratings On Alder BioPharmaceuticals, Inc. (ALDR)
Recently stock market analysts have updated their consensus ratings on shares of Alder BioPharmaceuticals, Inc. (ALDR). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.
Most recent broker ratings
04/21/2016 – Wells Fargo began new coverage on Alder BioPharmaceuticals, Inc. giving the company a “outperform” rating.
04/20/2016 – Brean Capital began new coverage on Alder BioPharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 45 price target on the stock.
03/29/2016 – Alder BioPharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Credit Suisse. They now have a USD 40 price target on the stock.
03/29/2016 – Alder BioPharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 62 price target on the stock.
08/06/2015 – Alder BioPharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 62 price target on the stock.
05/12/2015 – Alder BioPharmaceuticals, Inc. was downgraded to “sell” by analysts at Zacks. They now have a USD 31 price target on the stock.
06/11/2014 – Sanford C. Bernstein began new coverage on Alder BioPharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 30 price target on the stock.
Alder BioPharmaceuticals, Inc. has a 50 day moving average of 25.14 and a 200 day moving average of 28.07. The stock’s market capitalization is 1.10B, it has a 52-week low of 15.82 and a 52-week high of 54.90.
The share price of the company (ALDR) was down -0.44% during the last trading session, with a high of 25.67 and the volume of Alder BioPharmaceuticals, Inc. shares traded was 445392.
View other investors thoughts on Alder BioPharmaceuticals, Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.